Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

madaus gmbh - lévonorgestrel 150 µg; ethinylestradiol 30 µg - comprimé enrobé - 0,150 mg - 0,030 mg - lévonorgestrel 150 µg; ethinylestradiol 30 µg - levonorgestrel and ethinylestradiol

Union européenne - français - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - tériparatide - osteoporosis; osteoporosis, postmenopausal - homéostasie du calcium - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoires de l'aerocid - soufre précipité - suspension - 5,340 g - composition pour 100 ml de lotion > soufre précipité : 5,340 g > alun : 1,200 g

France - français - ANSES (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail)

intervet - clostridium chauvoei, clostridium haemolyticum, clostridium novyi, clostridium perfringens, clostridium septicum, clostridium sordellii, clostridium tetani - suspension injectable - bovins, ovins

France - français - ANSES (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail)

zoetis france - clostridium chauvoei, clostridium haemolyticum, clostridium novyi, clostridium perfringens, clostridium septicum, clostridium sordellii, clostridium tetani - suspension injectable - bovins, ovins

Canada - français - Health Canada

janssen inc - Époétine alpha - solution - 20000unité - Époétine alpha 20000unité - hematopoietic agents

Canada - français - Health Canada

janssen inc - Époétine alpha - solution - 1000unité - Époétine alpha 1000unité - hematopoietic agents

Canada - français - Health Canada

janssen inc - Époétine alpha - solution - 2000unité - Époétine alpha 2000unité - hematopoietic agents